MRI Features in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer

Sponsor
Sun Yat-sen University (Other)
Overall Status
Completed
CT.gov ID
NCT05609149
Collaborator
(none)
480
1
72.1
6.7

Study Details

Study Description

Brief Summary

This study investigates whether risk criteria based on MRI features could identify a cohort of patients with a good prognosis among those recommended for preoperative treatment by NCCN guidelines to avoid preoperative treatment with the likely good survival outcomes by primary surgery and more accurately indicate the response to the treatment and predict prognosis after neoadjuvant treatmen than radiographic TNM staging in the patients who received neoadjuvant therapy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: total mesorectal excision

Detailed Description

There is a lack of international consensus on the choice of preoperative treatment for patients with rectal cancer. Existing guidelines decide whether to administer preoperative therapy to patients with rectal cancer mainly based on the TNM system developed by AJCC/UICC, however, radiographic TNM staging is unsatisfactory in predicting the prognosis of patients with rectal cancer, due to inflammatory and fibrotic responses TNM re-staging is less accurate than pre-treatment. Studies have shown that high-resolution magnetic resonance imaging(MRI) accurately predicted pathologic findings such as CRM involvement, EMVI and TD and patients with MRI-detected CRM involvement, EMVI and TD are at risk for local and distant recurrence as well as poor overall survival. This retrospective study is designed to was to evaluate whether risk criteria based on MRI features can be used as a basis for neoadjuvant treatment decisions and more accurately indicate the response to the treatment and predict prognosis after neoadjuvant treatment than radiographic TNM staging. Patients with MRI-detected circumferential resection margin (CRM) involvement, extramural venous invasion (EMVI), or tumor deposits (TD) were defined as MRI high-risk.

Study Design

Study Type:
Observational
Actual Enrollment :
480 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Risk Criteria Based on MRI Features Outperform Radiographic TNM Staging in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer:A Single-Center, Open-Label, Retrospective, Observational Cohort Study
Actual Study Start Date :
Oct 30, 2016
Actual Primary Completion Date :
Nov 1, 2022
Actual Study Completion Date :
Nov 2, 2022

Arms and Interventions

Arm Intervention/Treatment
T3 Rectal cancer

Patients with T3 rectal cancer who underwent curative surgery.

Procedure: total mesorectal excision
patients must underwent total mesorectal excision

Outcome Measures

Primary Outcome Measures

  1. 3-year event-free survival rate [3 years after the surgery]

Secondary Outcome Measures

  1. 3-year overall survival rate [3 years after the surgery]

  2. Local recurrence [3 years after the surgery]

    Defined as an intrapelvic recurrence following a primary rectal cancer resection, with or without distal metastasis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Underwent primary rectal adenocarcinoma resection

  2. Received MRI scan before surgery

  3. Willing and able to provide written informed consent for participation in this study.

  4. Treatment-naive patients with histological or cytological documentation of rectal adenocarcinoma (<12 cm from the anal verge).

  5. Clinical stage of T3Nx or T1-3N+ at initial diagnosis

  6. Non-complicated primary tumor (complete obstruction, perforation, bleeding).

  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:
  1. Treated with transanal local excision

  2. with distant metastases at the time of initial diagnosis

  3. Subjects with a history of a prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer.

  4. Subjects with a history of any arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), myocardial infarction (MI), Transient Ischemic Attacks (TIA), or cerebralvascular accident (CVA).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University Guangzhou Guangdong China 510000

Sponsors and Collaborators

  • Sun Yat-sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yanhong Deng, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT05609149
Other Study ID Numbers:
  • GIHSYSU-30
First Posted:
Nov 8, 2022
Last Update Posted:
Nov 8, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yanhong Deng, Professor, Sun Yat-sen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 8, 2022